GENMAB A/S financials

Also U.S.-listed. GENMAB A/S is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: GMAB — Genmab A/S

GENMAB A/S

Country: DK Reporting currency: USD Latest annual report: 2026-03-31

LEI: 529900MTJPDPE4MHJ122

Source filing ↗

Financial statements (USD, as reported — unscaled; 91 line items across 3 annual periods)

Line item	2026	2025	2025
Income statement
Revenue	$896.0M	—	$715.0M
Cost of sales	$65.0M	—	$42.0M
Operating expenses	$716.0M	—	$527.0M
Operating profit (EBIT)	$180.0M	—	$188.0M
Finance costs	$150.0M	—	$45.0M
Profit before tax	$74.0M	—	$244.0M
Income tax expense	$21.0M	—	$49.0M
Profit for the year	$53.0M	—	$195.0M
Total comprehensive income	-$106.0M	—	$208.0M
Per share
Basic EPS	$0.84	—	$3.06
Diluted EPS	$0.83	—	$3.05
Free cash flow / share	$-0.03	—	$4.30
Cash flow statement
Cash generated from operations	$145.0M	—	$305.0M
Net cash from operating activities	$3.0M	—	$287.0M
Income taxes paid	$95.0M	—	$47.0M
Net cash from investing activities	-$9.0M	—	-$43.0M
Purchase of PP&E (capex)	$5.0M	—	$12.0M
Purchase of intangibles	$0	—	$18.0M
Net cash from financing activities	-$177.0M	—	-$13.0M
Repayments of borrowings	$63.0M	—	$0
Lease liability payments	$6.0M	—	$2.0M
Net change in cash	-$183.0M	—	$231.0M
Balance sheet
Total assets	$12.38B	$12.87B	—
Non-current assets	$9.80B	$9.99B	—
Property, plant & equipment	$143.0M	$153.0M	—
Right-of-use assets	$122.0M	$127.0M	—
Intangible assets & goodwill	$355.0M	$355.0M	—
Current assets	$2.57B	$2.88B	—
Inventories	$21.0M	$18.0M	—
Trade & other receivables	$968.0M	$1.11B	—
Cash & equivalents	$1.52B	$1.72B	$1.62B
Total equity	$5.68B	$5.85B	$5.30B
Non-current liabilities	$5.52B	$5.60B	—
Long-term borrowings	$4.93B	$5.00B	—
Lease liabilities (non-current)	$125.0M	$134.0M	—
Current liabilities	$1.18B	$1.43B	—
Short-term borrowings	$275.0M	$273.0M	—
Lease liabilities (current)	$18.0M	$18.0M	—
Deferred tax liabilities	$365.0M	$364.0M	—
Derived metrics
Free cash flow	-$2.0M	—	$275.0M
Operating margin	20.1%	—	26.3%
Net margin	5.9%	—	27.3%
Return on equity	0.9%	—	3.7%
Cash conversion ratio	0.06×	—	1.47×
Capex coverage	0.60×	—	23.92×
Other reported items
Adjustments For Amortisation Expense	$13.0M	—	$4.0M
Adjustments For Decrease Increase In Inventories	-$3.0M	—	-$3.0M
Adjustments For Decrease Increase In Trade and Other Receivables	$158.0M	—	$124.0M
Adjustments For Depreciation Expense	$16.0M	—	$12.0M
Adjustments For Finance Costs	$150.0M	—	$45.0M
Adjustments For Finance Income	$44.0M	—	$101.0M
Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss	$0	—	$1.0M
Adjustments For Increase Decrease In Contract Liabilities	-$7.0M	—	$0
Adjustments For Increase Decrease In Other Operating Payables	-$261.0M	—	-$46.0M
Adjustments For Sharebased Payments	$49.0M	—	$25.0M
Balances With Banks	$1.52B	—	$1.54B
Current Contract Liabilities	$24.0M	$24.0M	—
Current Tax Assets Current	$63.0M	$40.0M	—
Current Tax Liabilities Current	$0	$43.0M	—
Decrease Increase Through Tax On Sharebased Payment Transactions	$14.0M	—	$12.0M
Deferred Tax Assets	$173.0M	$171.0M	—
Effect of Exchange Rate Changes On Cash and Cash Equivalents	-$11.0M	—	$8.0M
Equity and Liabilities	$12.38B	$12.87B	—
Finance Income	$44.0M	—	$101.0M
Gains Losses On Cash Flow Hedges Before Tax	$5.0M	—	$0
Gains Losses On Cash Flow Hedges Net of Tax	$4.0M	—	$0
Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income	$1.0M	—	$0
Increase Decrease Through Exercise of Warrants Equity	$2.0M	—	$1.0M
Increase Decrease Through Sharebased Payment Transactions	$49.0M	—	$25.0M
Intangible Assets Other Than Goodwill	$8.95B	$9.12B	—
Interest Paid Classified As Operating Activities	$59.0M	—	$0
Interest Received Classified As Operating Activities	$14.0M	—	$31.0M
Issued Capital	$10.0M	$10.0M	—
Liabilities	$6.69B	$7.03B	—
Noncurrent Contract Liabilities	$88.0M	$95.0M	—
Noncurrent Investments Other Than Investments Accounted For Using Equity Method	$40.0M	$37.0M	—
Noncurrent Receivables	$22.0M	$22.0M	—
Other Comprehensive Income	-$159.0M	—	$13.0M
Other Comprehensive Income Net of Tax Exchange Differences On Translation	-$163.0M	—	$13.0M
Other Current Payables	$861.0M	$1.07B	—
Other Noncurrent Payables	$5.0M	$5.0M	—
Other Reserves	-$340.0M	-$181.0M	—
Payments To Acquire Or Redeem Entitys Shares	$96.0M	—	$0
Proceeds From Exercise of Warrants	$2.0M	—	$1.0M
Purchase of Investments Other Than Investments Accounted For Using Equity Method	$4.0M	—	$1.0M
Purchase of Treasury Shares	$96.0M	—	$63.0M
Research and Development Expense	$440.0M	—	$359.0M
Retained Earnings	$4.09B	$4.10B	—
Selling General and Administrative Expense	$166.0M	—	$126.0M
Share Premium	$1.92B	$1.92B	—
Shortterm Investments Classified As Cash Equivalents	$0	—	$80.0M

Methodology

Every line item above is a fact tagged in GENMAB A/S's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (USD), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.